Hypofractionated intensity-modulated radiotherapy for intermediate- And high-risk prostate cancer: A retrospective study

Nobuteru Kubo; Hidemasa Kawamura; Takahiro Oike; Hiro Sato; Mototaro Iwanaga; Tatsuji Mizukami; Akiko Adachi; Hiroshi Matsui; Kazuto Ito; Kazuhiro Suzuki; Takashi Nakano

doi:10.21873/invivo.11595

Hypofractionated intensity-modulated radiotherapy for intermediate- And high-risk prostate cancer: A retrospective study

Nobuteru Kubo^*, Hidemasa Kawamura, Takahiro Oike, Hiro Sato, Mototaro Iwanaga, Tatsuji Mizukami, Akiko Adachi, Hiroshi Matsui, Kazuto Ito, Kazuhiro Suzuki, Takashi Nakano

^*Corresponding author for this work

Diagnostic and Therapeutic Radiology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background/Aim: The aim of this study was to evaluate the efficacy and safety of hypofractionated intensitymodulated radiotherapy (IMRT) for intermediate- and highrisk prostate cancer. Patients and Methods: Seventy-five consecutive patients with intermediate- and high-risk prostate cancer treated with IMRT (63 Gy/21 fractions/7 weeks) between 2010 and 2013 were retrospectively analyzed. PSA relapse and adverse events were determined based on the Phoenix criteria and the Common Terminology Criteria for Adverse Events v4.0, respectively. Results: The 5-year PSA relapse-free rate, clinical relapse-free rate, and overall survival rate for all patients was 92.1%, 95.1%, and 92.9%, respectively. The incidence of late grade 2 gastrointestinal- and genitourinary-toxicity at 5 years was 1.3% and 17.1%, respectively. No grade 3 or greater toxicities were observed. Conclusion: These data indicate that hypofractionated IMRT (63 Gy in a total of 21 fractions with 3 fractions per week) is effective and safe for intermediate- and high-risk prostate cancer.

Original language	English
Pages (from-to)	1235-1241
Number of pages	7
Journal	In Vivo
Volume	33
Issue number	4
DOIs	https://doi.org/10.21873/invivo.11595
State	Published - 2019

Keywords

Hypofractionation
IMRT
Prostate cancer
Radiotherapy

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
Pharmacology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/invivo.11595

Cite this

@article{53fb8f114142454c8e3322e9a2dee44c,

title = "Hypofractionated intensity-modulated radiotherapy for intermediate- And high-risk prostate cancer: A retrospective study",

abstract = "Background/Aim: The aim of this study was to evaluate the efficacy and safety of hypofractionated intensitymodulated radiotherapy (IMRT) for intermediate- and highrisk prostate cancer. Patients and Methods: Seventy-five consecutive patients with intermediate- and high-risk prostate cancer treated with IMRT (63 Gy/21 fractions/7 weeks) between 2010 and 2013 were retrospectively analyzed. PSA relapse and adverse events were determined based on the Phoenix criteria and the Common Terminology Criteria for Adverse Events v4.0, respectively. Results: The 5-year PSA relapse-free rate, clinical relapse-free rate, and overall survival rate for all patients was 92.1%, 95.1%, and 92.9%, respectively. The incidence of late grade 2 gastrointestinal- and genitourinary-toxicity at 5 years was 1.3% and 17.1%, respectively. No grade 3 or greater toxicities were observed. Conclusion: These data indicate that hypofractionated IMRT (63 Gy in a total of 21 fractions with 3 fractions per week) is effective and safe for intermediate- and high-risk prostate cancer.",

keywords = "Hypofractionation, IMRT, Prostate cancer, Radiotherapy",

author = "Nobuteru Kubo and Hidemasa Kawamura and Takahiro Oike and Hiro Sato and Mototaro Iwanaga and Tatsuji Mizukami and Akiko Adachi and Hiroshi Matsui and Kazuto Ito and Kazuhiro Suzuki and Takashi Nakano",

year = "2019",

doi = "10.21873/invivo.11595",

language = "英語",

volume = "33",

pages = "1235--1241",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "4",

}

TY - JOUR

T1 - Hypofractionated intensity-modulated radiotherapy for intermediate- And high-risk prostate cancer

T2 - A retrospective study

AU - Kubo, Nobuteru

AU - Kawamura, Hidemasa

AU - Oike, Takahiro

AU - Sato, Hiro

AU - Iwanaga, Mototaro

AU - Mizukami, Tatsuji

AU - Adachi, Akiko

AU - Matsui, Hiroshi

AU - Ito, Kazuto

AU - Suzuki, Kazuhiro

AU - Nakano, Takashi

PY - 2019

Y1 - 2019

N2 - Background/Aim: The aim of this study was to evaluate the efficacy and safety of hypofractionated intensitymodulated radiotherapy (IMRT) for intermediate- and highrisk prostate cancer. Patients and Methods: Seventy-five consecutive patients with intermediate- and high-risk prostate cancer treated with IMRT (63 Gy/21 fractions/7 weeks) between 2010 and 2013 were retrospectively analyzed. PSA relapse and adverse events were determined based on the Phoenix criteria and the Common Terminology Criteria for Adverse Events v4.0, respectively. Results: The 5-year PSA relapse-free rate, clinical relapse-free rate, and overall survival rate for all patients was 92.1%, 95.1%, and 92.9%, respectively. The incidence of late grade 2 gastrointestinal- and genitourinary-toxicity at 5 years was 1.3% and 17.1%, respectively. No grade 3 or greater toxicities were observed. Conclusion: These data indicate that hypofractionated IMRT (63 Gy in a total of 21 fractions with 3 fractions per week) is effective and safe for intermediate- and high-risk prostate cancer.

AB - Background/Aim: The aim of this study was to evaluate the efficacy and safety of hypofractionated intensitymodulated radiotherapy (IMRT) for intermediate- and highrisk prostate cancer. Patients and Methods: Seventy-five consecutive patients with intermediate- and high-risk prostate cancer treated with IMRT (63 Gy/21 fractions/7 weeks) between 2010 and 2013 were retrospectively analyzed. PSA relapse and adverse events were determined based on the Phoenix criteria and the Common Terminology Criteria for Adverse Events v4.0, respectively. Results: The 5-year PSA relapse-free rate, clinical relapse-free rate, and overall survival rate for all patients was 92.1%, 95.1%, and 92.9%, respectively. The incidence of late grade 2 gastrointestinal- and genitourinary-toxicity at 5 years was 1.3% and 17.1%, respectively. No grade 3 or greater toxicities were observed. Conclusion: These data indicate that hypofractionated IMRT (63 Gy in a total of 21 fractions with 3 fractions per week) is effective and safe for intermediate- and high-risk prostate cancer.

KW - Hypofractionation

KW - IMRT

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85069285348&partnerID=8YFLogxK

U2 - 10.21873/invivo.11595

DO - 10.21873/invivo.11595

M3 - 学術論文

C2 - 31280214

AN - SCOPUS:85069285348

SN - 0258-851X

VL - 33

SP - 1235

EP - 1241

JO - In Vivo

JF - In Vivo

IS - 4

ER -

Hypofractionated intensity-modulated radiotherapy for intermediate- And high-risk prostate cancer: A retrospective study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this